Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jan. 31, 2020	Jan. 31, 2019
Operating activities
Net loss	$ (2,980)	$ (1,366)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	939	860
Deferred income taxes	12	(15)
Interest income on Series D Convertible Note		(848)
Net gain on sales of marketable securities		(330)
Unrealized (gain) loss on investments - Hedge Funds	(520)	52
Provision for doubtful accounts	48	9
Non-cash compensation	411	172
Amortization of debt discount	54	5
Change in assets and liabilities:
Trade accounts receivable	77	(78)
Prepaid expenses and other current assets	181	(186)
Other assets	(38)	(82)
Accounts payable and accrued expenses	(252)	296
Due to/from related parties	126	588
Other current liabilities		39
Other liabilities	42	(15)
Net cash used in operating activities	(1,900)	(899)
Investing activities
Purchases of property and equipment	(456)	(58)
Proceeds from sale and maturity of marketable securities, net		25,031
Investment in Rafael Pharmaceuticals		(55,870)
Net cash used in investing activities	(456)	(30,897)
Financing activities
Contribution from noncontrolling interest of consolidated entity		4,587
Repayment of Loan from Rafael Pharmaceuticals		3,300
Proceeds from exercise of options		163
Proceed from sale of shares		7,777
Proceeds from convertible notes payable - Related Party		15,000
Payments for taxes related to shares withheld for employee taxes	(116)
Net cash (used in) provided by financing activities	(116)	30,827
Effect of exchange rate changes on cash and cash equivalents	(30)	(65)
Net decrease in cash and cash equivalents	(2,502)	(1,034)
Cash and cash equivalents at beginning of period	12,024	15,803
Cash and cash equivalents at end of period	9,522	14,769
Supplemental Schedule of Non-Cash Investing and Financing Activities
Adoption effect of ASU 2016-01		39
Beneficial conversion feature of convertible debt - Related Party		71
Debt and accrued interest converted to Series D Preferred Stock		10,848
Related Party deposit utilized to purchase Class B Common Stock		864
Conversion of LipoMedix Bridge Note	200
Conversions of related party convertible notes payable and accrued interest	$ 15,668